Close Menu

NEW YORK – Strata Oncology on Wednesday said it will soon begin enrollment in the Sentinel trial, in which the Michigan-based precision oncology company will evaluate its investigational liquid biopsy assay in patients with solid tumors to determine if the test can detect disease recurrence and monitor treatment effectiveness.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.